Cerus ( CERS) was one of the best performers of Friday's session. After the previous close, the biotech company said it swung to a fourth-quarter profit that easily beat Wall Street's estimates. Cerus was recently up 33 cents, or 5.8%, to $6.07.

Telik ( TELK) was also higher after the company late Thursday posted a narrower-than-expected fourth-quarter loss. The stock was rising 38 cents, or 7%, to $5.85.

On the other hand, Gene Logic ( GLGC) slid 4.2% to $1.82 after the company said it may spin off its genomics division, which was once the company's core business.

PDL BioPharma ( PDLI) was also moving lower more than a day after the company missed fourth-quarter earnings targets. The stock was losing 26 cents, or 1.3%, to $19.45.

Among health care winners of the session, NeoPharm ( NEOL) surged 29.8% to $2.31. Celgene ( CELG) was adding 2.8% at $56.41. GlaxoSmithKline ( GSK) was higher by 1.1% to $57.

Among decliners, Forest Laboratories ( FRX) was off 1.2% at $54.34. Humana ( HUM) was losing 1.1% to $61.61. UnitedHealth Group ( UNH) was down 1% to $53.19.

More from Investing

Tesla CEO Elon Musk Is a Rock Star: Kiss Icon Gene Simmons

Tesla CEO Elon Musk Is a Rock Star: Kiss Icon Gene Simmons

Macy's Vs. J.C. Penney: Which Department Store Is Just Trying to Survive?

Macy's Vs. J.C. Penney: Which Department Store Is Just Trying to Survive?

The Best Investment Advice? Stay Diversified

The Best Investment Advice? Stay Diversified

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

After PayPal Buys iZettle, Pay-Tech Firms Could Process These Deals

After PayPal Buys iZettle, Pay-Tech Firms Could Process These Deals